Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia

CALGARY, ALBERTA--(Marketwired - July 27, 2015) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM), a clinical-stage autologous cell-therapy company, announced another milestone today in its international phase-2 clinical trial for critical limb ischemia (CLI): enrollment of its 20th patient. The double-blind, randomized, placebo-controlled trial currently recruits participants at six sites in Canada and South Africa under the same clinical protocol and will ultimately enroll approximately 100 participants with CLI.

The trial studies the efficacy of the company's lead product, ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are grown from a patient's own blood and, once injected into his or her diseased tissue, are able to support the formation of new blood vessels.

"Our clinical trial is enrolling participants at an accelerated pace as a direct result of our ability to continue recruiting clinical sites," said Dr. Hardean E. Achneck, vice president of clinical research and operations at Hemostemix. "We enrolled 20 participants and have already treated 15, which is remarkable because five of our six clinical sites only began enrolling at the end of March."

"This milestone demonstrates the strength of our clinical program and reflects our ability to deliver on our clinical development goals," said Dr. Elmar Burchardt, president and CEO of Hemostemix. "It also attests to the need for a nonsurgical, regenerative cell therapy that addresses CLI. We are committed to relieving the suffering of patients with this severe and debilitating disease through our innovative cell therapy."

About Critical Limb Ischemia (CLI)

CLI is a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. About half of CLI patients either die or require amputation of the affected limb within one year of diagnosis. Demand for a treatment is on the rise, as CLI predominately affects the growing population aged 50 and older.

About Hemostemix

Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. For more information, visit hemostemix.com or email office@hemostemix.com.

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential", and similar expressions, or that events or conditions "will", "would", "may", "could", or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.